StockData
Neuphoria Therapeutics Inc. logo

Neuphoria Therapeutics Inc. (NEUP) stock

NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026Score 5/30
$2.55−0.03 (-1.16%)

Close on Nov 13, 2026Market cap $76.66KP/E –Yield –

Earnings

Neuphoria Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Neuphoria Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2025ended Mar 31, 2025May 20, 2025after the close–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Neuphoria Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Neuphoria Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Neuphoria Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. PRESS RELEASE, DATED AS OF JULY 23, 2026
    Update
  2. INVESTOR PRESENTATION OF SCANCELL HOLDINGS PLC, DATED JULY 2026
    Update
  3. PRESS RELEASE DATED OCTOBER 27, 2025
    News
  4. PRESS RELEASE, DATED OCTOBER 20, 2025
    News
  5. PRESS RELEASE DATED MAY 20, 2025
    Results
  6. The following description of the capital stock of Neuphoria Therapeutics
    News
  7. PRESS RELEASE, DATED DECEMBER 23, 2024
    News
  8. PRESS RELEASE, DATED DECEMBER 16, 2024, ISSUED BY BIONOMICS LIMITED
    News
  9. AMENDING AGREEMENT TO SCHEME IMPLEMENTATION AGREEMENT, DATED OCTOBER 24, 2024, BETWEEN BIONOMICS LIMITED AND NEUPHORIA THERAPEUTICS INC
    News
  10. SCHEME BOOKLET, DATED NOVEMBER 8, 2024
    News
  11. PRESS RELEASE, DATED NOVEMBER 8, 2024, ISSUED BY BIONOMICS LIMITED
    News
  12. A. The Company and each Investor is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the 1933 Act (as defined below);
    6-K
  13. The parties hereby agree as follows:
    6-K
  14. PRE-FUNDED WARRANT TO PURCHASE ADSs
    6-K
  15. Hal f-Year Report – 31 December 2023
    6-K

See a number that looks wrong?